Valneva Shares Decline by 2.92% Despite a 45% Rally Over the Year

Context of Today's Decline

Today's decline in Valneva occurs in a context of profit-taking after a significant rally. Over three months, the stock has increased by 26.17%, and the performance over one year reaches 44.91%. The price is currently above its 50-day moving average, which is at 4.30 euros, and well beyond the 200-day average at 3.79 euros, confirming a medium and long-term upward trend.

However, the stock is approaching its upper Bollinger band, set at 5.09 euros, a level very close to the resistance identified at 5.08 euros. This threshold constitutes a significant technical zone that the price has not yet managed to break through. The RSI, at 57, remains in neutral territory, indicating neither overbought nor oversold conditions and leaves room for fluctuation in both directions in the short term.

Key Upcoming Dates for Valneva

The next crucial milestone for Valneva is the publication of its 2025 annual results, scheduled for March 18, which is in a week. This event will be followed by the results of the first quarter of 2026 on May 7, and then the general meeting scheduled for June 1. These milestones will provide increased visibility on the operational and financial trajectory of the laboratory.

The decline this Wednesday also occurs in an unfavorable market environment. The CAC 40 is down 0.58% in session, at 8,010.43 points, while the DAX is down 1.58%. The VIX, a volatility index measured on March 6 at 29.49, signals a high level of tension on international markets. Valneva's negative beta, at -0.31, however, recalls the stock's historically low correlation with major indices, a characteristic typical of mid-sized biotechnological companies.